scholarly journals Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study

2016 ◽  
Vol 63 (1) ◽  
pp. 122-132 ◽  
Author(s):  
Sarah Lilian Pett ◽  
Janaki Amin ◽  
Andrejz Horban ◽  
Jaime Andrade-Villanueva ◽  
Marcelo Losso ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Hiv Replication ◽  
Protease Inhibitor Regimen ◽  
Inhibitor Regimen ◽  
Nucleotide Reverse Transcriptase Inhibitor ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection

AIDS ◽  
1998 ◽  
Vol 12 (14) ◽  
pp. 1833-1844 ◽  
Author(s):  
Janis V. Giorgi ◽  
Martin A. Majchrowicz ◽  
Timothy D. Johnson ◽  
Patricia Hultin ◽  
Jose Matud ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Inhibitor Therapy ◽  
Previously Treated ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

scholarly journals Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0242405
Author(s):  
Dwight E. Yin ◽  
Christina Ludema ◽  
Stephen R. Cole ◽  
Carol E. Golin ◽  
William C. Miller ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Protease Inhibitor ◽  
Reverse Transcriptase ◽  
Nucleoside Reverse Transcriptase Inhibitor ◽  
Transcriptase Inhibitor ◽  
Continuous Therapy ◽  
Time To Treatment ◽  
Treatment Naïve ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

Background Choice of initial antiretroviral therapy regimen may help children with HIV maintain optimal, continuous therapy. We assessed treatment-naïve children for differences in time to treatment disruption across randomly-assigned protease inhibitor versus non-nucleoside reverse transcriptase inhibitor-based initial antiretroviral therapy. Methods We performed a secondary analysis of a multicenter phase 2/3, randomized, open-label trial in Europe, North and South America from 2002 to 2009. Children aged 31 days to <18 years, who were living with HIV-1 and treatment-naive, were randomized to antiretroviral therapy with two nucleoside reverse transcriptase inhibitors plus a protease inhibitor or non-nucleoside reverse transcriptase inhibitor. Time to first documented treatment disruption to any component of antiretroviral therapy, derived from treatment records and adherence questionnaires, was analyzed using Kaplan-Meier estimators and Cox proportional hazards models. Results The modified intention-to-treat analysis included 263 participants. Seventy-two percent (n = 190) of participants experienced at least one treatment disruption during study. At 4 years, treatment disruption probabilities were 70% (protease inhibitor) vs. 63% (non-nucleoside reverse transcriptase inhibitor). The unadjusted hazard ratio (HR) for treatment disruptions comparing protease inhibitor vs. non-nucleoside reverse transcriptase inhibitor-based regimens was 1.19, 95% confidence interval [CI] 0.88–1.61 (adjusted HR 1.24, 95% CI 0.91–1.68). By study end, treatment disruption probabilities converged (protease inhibitor 81%, non-nucleoside reverse transcriptase inhibitor 84%) with unadjusted HR 1.11, 95% CI 0.84–1.48 (adjusted HR 1.13, 95% CI 0.84–1.50). Reported reasons for treatment disruptions suggested that participants on protease inhibitors experienced greater tolerability problems. Conclusions Children had similar time to treatment disruption for initial protease inhibitor and non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy, despite greater reported tolerability problems with protease inhibitor regimens. Initial pediatric antiretroviral therapy with either a protease inhibitor or non-nucleoside reverse transcriptase inhibitor may be acceptable for maintaining optimal, continuous therapy.

scholarly journals Characterization of UC781-Tenofovir Combination Gel Products for HIV-1 Infection Prevention in anEx VivoEctocervical Model

2012 ◽  
Vol 56 (6) ◽  
pp. 3058-3066 ◽  
Author(s):  
Marilyn Cost ◽  
Charlene S. Dezzutti ◽  
Meredith R. Clark ◽  
David R. Friend ◽  
Ayman Akil ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Drug Candidates ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
Drug Concentrations ◽  
Nucleotide Reverse Transcriptase Inhibitor ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

ABSTRACTHIV continues to be a problem worldwide. Topical vaginal microbicides represent one option being evaluated to stop the spread of HIV. With drug candidates that have a specific action against HIV now being studied, it is important that, when appropriate and based on the mechanism of action, the drug permeates the tissue so that it can be delivered to specific targets which reside there. Novel formulations of the nucleotide reverse transcriptase inhibitor tenofovir (TFV) and the nonnucleoside reverse transcriptase inhibitor UC781 have been developed and evaluated here. Gels with three distinct rheological properties were prepared. The three gels released both UC781 and TFV underin vitroconditions at concentrations equal to or above the reported 50% effective concentrations (EC50s). The drug concentrations in ectocervical tissues were well in excess of the reported EC50s. The gels maintain ectocervical viability and prevent infection of ectocervical explants after a HIV-1 challenge. This study successfully demonstrates the feasibility of using this novel combination of antiretroviral agents in an aqueous gel as an HIV infection preventative.

Sign in / Sign up

Export Citation Format

Share Document